Gastroenterologie
a hepatologie

The impact of polymorphisms PNPLA3 rs738409 and TM6SF2 rs58542926 of the donor and recipient respectively on long-term patient survival after liver transplantation

Irena Míková¹, Milan Jirsa ^{Orcid.org  2}, Eva Sticová ^{Orcid.org  3}, Pavel Trunečka¹, Magdaléna Neřoldová², Jan Mareš⁴

+ Affiliation
¹ Klinika hepatogastroenterologie, Transplantcentrum, IKEM, Praha
² Laboratoř experimentální hepatologie, Centrum experimentální medicíny, Transplantcentrum, IKEM, Praha
³ Pracoviště klinické a experimentální patologie, Transplantcentrum, IKEM, Praha
⁴ Oddělení datové vědy, Institut klinické a experimentální medicíny, Praha

Summary

Introduction: The variants rs738409 c.444C>G (p.I148M) in patatin-like phospholipase domain-containing 3 (PNPLA3) and rs58542926 c.499G>A (p.E167K) in TM6SF2 (transmembrane 6 superfamily member 2) are significant genetic risk factors of development and progression of non-alcoholic fatty liver disease (NAFLD). In both variants, increased liver-specific mortality was described, while the impact on all-cause mortality was not proved. The aim of the study was to evaluate the impact of PNPLA3 rs738409 and TM6SF2 rs58542926 genotypes of the donor and recipient respectively on long-term patient survival after LT. Methods: We evaluated long-term patient survival in a cohort of 268 adult LT recipients, in whom PNPLA3 rs738409 and TM6SF2 rs58542926 genotypes of the donor and recipient respectively were available and steatosis was evaluated in liver graft biopsy 6–30 months after LT. The median fol low-up was 17 years. The Kaplan-Meier model was used for the survival estimates and the Cox proportional hazard model was used to assess the predictive value of the chosen variables. Results: Increased recipient age (P < 0.001), male sex (P = 0.014), alcoholic (P = 0.021) or HCV (P = 0.042) etiology of liver cirrhosis, and presence of hepatocellular carcinoma (P = 0.009) negatively influenced long-term patient survival after LT. PNPLA3 rs738409 and TM6SF2 rs58542926 genotypes of the recipient and donor respectively had no effect on patient survival. Conclusion: Although PNPLA3 c.444G and TM6SF2 c.499A variants of the donor increase the risk of steatosis of the liver graft after LT, we did not prove a negative impact of these genotypes of the donor and recipient on long-term patient survival after LT.

Keywords

PNPLA3, TM6SF2, steatosis, MASLD, NAFLD, liver transplantation, patient survival

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. EASL. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64(6): 1388–1402. doi: 10.1007/s00125-016-3910-y.
2. Calori G, Lattuada G, Ragogna F et al. Fatty liver index and mortality: the cremona study in the 15th year of follow-up. Hepatology 2011; 54(1): 145–152. doi: 10.1002/hep.24356.
3. Haldar D, Kern B, Hodson J et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study. J Hepatol 2019; 71(2): 313–322. doi: 10.1016/j.jhep.2019.04.011.
4. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 2024; S0168-8278(24)00329-5. doi: 10.1016/j.jhep.2024.04.031.
5. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2(11): 901–910. doi: 10.1016/S2213-8587(14)70032-4.
6. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018; 68(2): 268–279. doi: 10.1016/j.jhep.2017.09.003.
7. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40(12): 1461–1465. doi: 10.1038/ng.257.
8. Kozlitina J, Smagris E, Stender S et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46(4): 352–356. doi: 10.1038/ng.2901.
9. Wang Y, Kory N, BasuRay S et al. PNPLA3, CGI-58, and inhibition of hepatic triglyceride hydrolysis in mice. Hepatology 2019; 69(6): 2427–2441. doi: 10.1002/hep.30583.
10. Borén J, Adiels M, Björnson E et al. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. JCI Insight 2020; 5(24): e144079. doi: 10.1172/jci.insight.144079.
11. Valenti L, Al-Serri A, Daly AK et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51(4): 1209–1217. doi: 10.1002/hep.23622.
12. Rotman Y, Koh C, Zmuda JM et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52(3): 894–903. doi: 10.1002/hep.23759.
13. Dongiovanni P, Petta S, Maglio C et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular dis ease. Hepatology 2015; 61(2): 506–514. doi: 10.1002/hep.27490.
14. Koo BK, Joo SK, Kim D et al. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2018; 33(6): 1277–1285. doi: 10.1111/jgh.14056.
15. Ekstedt M, Hagström H, Nasr P et al. Fibrosis stage is the strongest predictor for dis ease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61(5): 1547–1554. doi: 10.1002/hep.27368.
16. Liu Y, Zhong GC, Tan HY et al. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Sci Rep 2019; 9(1): 11124. doi: 10.1038/s41598-019-47687-3.
17. Söderberg C, Stål P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51(2): 595–602. doi: 10.1002/hep.23314.
18. Gellert-Kristensen H, Tybjaerg-Hansen A, Nordestgaard BG et al. Genetic risk of fatty liver disease and mortality in the general population: a Mendelian randomization study. Liver Int 2023; 43(9): 1955–1965. doi: 10.1111/liv.15629.
19. Käräjämäki AJ, Hukkanen J, Kauma H et al. Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts in creased total mortality in subjects with NAFLD (OPERA study). Scand J Clin Lab Invest 2020; 80(2): 106–113. doi: 10.1080/00365513.2019.1700428.
20. Hejlova I, Honsova E, Sticova E et al. Prevalence and risk factors of steatosis after liver transplantation and patient outcomes. Liver Transplant 2016; 22(5): 644–655. doi: 10.1002/lt.24393.
21. Mikova I, Neroldova M, Hubacek JA et al. Donor PNPLA3 and TM6SF2 variant alleles confer additive risks for graft steatosis after liver transplantation. Transplantation 2020; 104(3): 526–534. doi: 10.1097/TP.0000000000002876.
22. Trunecka P, Mikova I, Dlouha D et al. Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study. Dig Liver Dis 2018; 50(5): 490–495. doi: 10.1016/j.dld.2017.12.030.
23. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41(6): 1313–1321. doi: 10.1002/hep.20701.
24. Krawczyk M, Rau M, Schattenberg JM et al. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. J Lipid Res 2017; 58(1): 247–255. doi: 10.1194/jlr.P067454.
25. Speliotes EK, Butler JL, Palmer CD et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010; 52(3): 904–912. doi: 10.1002/hep.23768.
26. Anstee QM, Darlay R, Cockell S et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol 2020; 73(3): 505–515. doi: 10.1016/j.jhep.2020.04.003.
27. Zain SM, Mohamed R, Mahadeva S et al. A multi-ethnic study of a PNPLA3 gene variant and its association with dis ease severity in non-alcoholic fatty liver dis ease. Hum Genet 2012; 131(7): 1145–1152. doi: 10.1007/s00439-012-1141-y.
28. Targher G, Byrne CD, Lonardo A et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016; 65(3): 589–600. doi: 10.1016/j.jhep.2016.05.013.
29. Xia M, Ma S, Huang Q et al. NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study. Aliment Pharmacol Ther 2022; 55(6): 705–721. doi: 10.1111/apt.16772.
30. Roberts MS, Angus DC, Bryce CL et al. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004; 10(7): 886–897. doi: 10.1002/lt.20137.
31. Dumortier J, Guillaud O, Adham M et al. Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. Am J Gastroenterol 2007; 102(5): 1032–1041. doi: 10.1111/j.1572-0241.2007.01079.x.
32. Burra P, Senzolo M, Adam R et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant 2010; 10(1): 138–148. doi: 10.1111/j.1600-6143.2009. 2869.x.
33. Belli LS, Perricone G, Adam R et al. Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol 2018; 69(4): 810–817. doi: 10.1016/j.jhep.2018.06.010.